Docetaxel and Ifosfamide for Advanced Cancer
Author Information
Author(s): Marx G, Lewis C, Hall K, Levi J, Ackland S
Primary Institution: Prince of Wales Hospital, Sydney, Australia
Hypothesis
The study aims to determine the maximum tolerated dose of docetaxel combined with ifosfamide in treating advanced cancer.
Conclusion
The combination of docetaxel and ifosfamide is feasible and effective for patients with advanced cancer.
Supporting Evidence
- Three complete responses and three partial responses were observed.
- The maximum tolerated dose was identified as docetaxel 75 mg/m2 and ifosfamide 2750 mg/m2/day.
- Neutropenia was the most common dose-limiting toxicity.
Takeaway
Doctors tested a new medicine combination to help people with serious cancer, and it worked well for some patients.
Methodology
Patients received docetaxel and ifosfamide in a controlled setting to assess toxicity and effectiveness.
Limitations
The study had a small sample size and was limited to patients with specific cancer types.
Participant Demographics
Median age was 49 years, with 18 males and 13 females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website